Siemens Healthineers is confronting a dual financial challenge as it moves deeper into its fiscal year. The company anticipates a hit of up to €500 million to its earnings from U.S. tariffs, a significant headwind that has contributed to its share price trading approximately 18% below its level at the start of the year. This pressure is expected to be fully realized in the second quarter of 2026.
A Manufacturing Footprint Meets Trade Policy
The core issue stems from the firm’s global production setup. Over half of the projected tariff burden is attributed to exports from its European facilities to the United States. Compounding this is an estimated currency disadvantage of €200 to €250 million on operating profit. This combination creates a substantial drag on performance.
Recent segment results highlight the growing divergence between revenue growth and profitability. Within the Imaging division, sales increased by 6.5%, yet the operating margin contracted from 24.2% to 20.6%. The contrast is even starker in Laboratory Diagnostics, where the adjusted operating margin has dwindled to just 2.1%. Further complications arise from the Chinese market, where structural reforms under a state anti-corruption campaign have centralized procurement and reduced reimbursement rates, weighing on business.
Strategic Responses and a Silver Lining
Management has outlined a three-pronged strategy to counter these pressures: implementing price increases, pursuing cost savings, and, if necessary, relocating production capacity to the U.S. The latter option represents a major structural shift that would require significant time and capital investment.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
Amid the challenges, one product has benefited from the current trade environment. The Atellica LumIQ Analyzer, a portable device for bedside urinalysis launched in early April, is manufactured in Sudbury, UK. This origin currently provides a tariff advantage for exports to the American market.
Despite the near-term hurdles, the company’s full-year guidance remains unchanged. Siemens Healthineers continues to forecast comparable revenue growth of 5 to 6 percent and an adjusted earnings per share range of €2.20 to €2.40. However, for the upcoming second quarter, growth is expected to fall below this target range, with conditions in China remaining difficult.
Upcoming Events and Financial Overhang
Two key dates are on the horizon for investors. The management team is scheduled to present at the HSBC Global Investment Summit in Hong Kong on April 14. This will be followed by the release of Q2 results and an analyst call on May 7. These events may provide clearer signals on whether the Diagnostics business in China is beginning to stabilize.
Running parallel to operational challenges is the planned corporate separation from its parent, Siemens AG. This move forces Siemens Healthineers to refinance loans worth up to €13.9 billion that were previously guaranteed by the parent company. Analysts at Barclays estimate this will lead to additional interest expenses of approximately €74 million in the current fiscal year alone—a further squeeze on an already constrained earnings outlook.
Ad
Siemens Healthineers Stock: Buy or Sell?! New Siemens Healthineers Analysis from April 7 delivers the answer:
The latest Siemens Healthineers figures speak for themselves: Urgent action needed for Siemens Healthineers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 7.
Siemens Healthineers: Buy or sell? Read more here...
